News Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013


Aug 8, 2019
Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 (bempegaldesleukin) Program

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion...

Aug 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for...

Jul 30, 2019

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of U.S.-based financial markets. Howard Robin, President...

Jun 13, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in...

Jun 11, 2019

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00...


Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide